Cargando…
PD-1抑制剂Nivolumab治疗相关的皮肤毒性1例
BACKGROUND AND OBJECTIVE: Nivolumab is an checkpoint inhibitor combining with programmed death-1 (PD-1) receptor on T cells, which can block the interactions between PD-1 and programmed death ligands (PD-L), including PD-L1 and PD-L2. And then block the immunosuppression mediated by the PD-1 pathway...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500497/ https://www.ncbi.nlm.nih.gov/pubmed/31014445 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.09 |